Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial

Journal of Clinical Oncology

Volumn 20, Issue 17, 2002, Pages 3578-3585

  Kosmidis, Paris ^a   Mylonakis, Nick ^a   Nicolaides, Costas ^a   Kalophonos, Charalabos ^a   Samantas, Epaminontas ^a   Boukovinas, John ^a   Fountzilas, George ^a   Skarlos, Dimosthenis ^a   Economopoulos, Theophanis ^a   Tsavdaridis, Dimitrios ^a   Papakostas, Pavlos ^a   Bacoyiannis, Charalabos ^a   Dimopoulos, Meletios ^a  

^a HYGEIA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; ONDANSETRON; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; GREECE; HEALTH CARE COSTS; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0036729263     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.12.112     Document Type: Article

References (34)

1. Non small cell lung cancer
2. Cancer statistics, 1998
3. Cancer statistics, 2001
4. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials - Non-small Cell Lung Cancer Collaborative Group
5. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
6. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer
7. Gemcitabine: A pharmacologic and clinical overview
8. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview
9. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
10. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
11. Weekly gemcitabine and monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer
12. Taxol: Twenty years later, the story unfolds
13. A phase II study of taxol in patients with untreated advanced non-small-cell lung cancer
14. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: A phase II trial
15. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer
16. Sequences of taxol and cisplatin: A phase I and pharmacologic study
17. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting
18. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
19. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
20. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
21. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
22. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
23. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
24. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial-Hellenic Cooperative Oncology Group (HeCOG)
25. Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer
26. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
27. Results of a phase II study with Taxol (paclitaxel) and Gemzar (gemcitabine) in metastatic non-small cell lung cancer (NSCLC)
28. Phase II study of gemcitabine and paclitaxel in metastatic non-small cell lung cancer
29. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E 1594: A phase III trial in patients with metastatic non-small cell lung carcinoma
30. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer
31. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer
32. An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
33. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial